Overview


Angiopoietin is a protein that binds mainly to a receptor on endothelial cells and promotes the maturation and stability of blood vessels. It is a growth factor that plays a significant role in the embryonic and postnatal angiogenesis. There are four identified angiopoietins ANGPT1ANGPT2ANGPTL3ANGPT4. Majorly ANGPT1ANGPT2 are known where ANGPT1 is critical for vessels maturation, migration, adhesion and survival on the other hand ANGPT2 promotes cell death an disrupts vascularization. 

Angiopoietin plays a crucial role in angiogenesis where the formation of new blood vessels from existing ones occurs. They are the ligands of Tie receptors which play a crucial role in angiogenesis, and their inhibition can prevent many tumours growths even in later stages of development. Angiopoietin inhibitors are a class of therapeutics agents that target the angiopoietin signalling pathway. Angiopoietin inhibitors typically targets Ang-2 and its interaction with Tie 2 receptors. By inhibiting Ang 2 activity, these drugs aim to modulate angiogenesis and vascular permeability. This approach can be relevant in various medical conditions where abnormal angiogenesis contributes to disease pathogenesis. With growing research and clinical trials, more specific and selective angiopoietin inhibitor therapeutics are developed and target to treat different diseases such as cancer, pulmonary disorders etc.

FutureWise Market Research has published a report that provides an insightful analysis of Angiopoietin Inhibitors Therapeutic Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Angiopoietin Inhibitors Therapeutic Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • GlaxoSmithKline
  • Merck KGaA
  • Agenus
  • Amgen
  • Pfizer
  • Regeneron Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent players in the Angiopoietin Inhibitors Therapeutic Market

  • Takeda has signed a licensing agreement with HUTCHMED (China) limited to expand the commercialization and development of fruquintinib outside of Hong Kong, mainland China and Macau, starting January 2023.

The rise in the incidence of various cancers affecting many individuals is fuelling the Angiopoietin inhibitor therapeutic market growth. The rising worldwide burden of different types of cancer such as lung cancer, throat cancer, breast cancer, prostate cancer will accelerate the market growth. More research and development efforts are made to provide the best possible treatments to the affected individuals using therapeutics, creating new growth opportunities. Support from private and public organizations, creating more awareness and safety protocols for individuals, and providing them with care and proper treatment is a good initiative boosting the market growth. 

The use of innovative technologies and advancement in the treatment drives this industry. The industry is also fuelled by angiopoietin inhibitor therapeutic knowledge and aiding them with the best possible drug treatments. The overall market growth is expected to face significant constraints over the projected period. These constraints include a lack of highly qualified researchers, limited therapy for individuals in developing countries, and lack of awareness that are hampering the market growth to a certain extent.

By Types

  • Angiopoietin-1 inhibitors (AMG780, AB3120)
  • Angiopoietin-2 inhibitors (Trebananib, MEDI3617, REGN910 CVX-060)

By Applications

  • Solid Tumours and Cancers
  • Vascular diseases (Diabetic Retinopathy, Diabetic Nephropathy)
  • Asthma

By Distribution Channels

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America currently dominates the market in terms of market share and revenue, and this trend is expected to continue during the projected period. The market growth in this region is influenced by various factors such as the increase in cancer incidence, the existence of significant market competitors, and the introduction of new products. Meanwhile, the Asia-Pacific region is expected to experience the highest growth rate during the forecast period due to various reasons such as the increasing awareness of early diagnosis, high healthcare expenditure, significant unmet clinical needs of patients, and effective treatment in the rapidly growing countries like India and China.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Angiopoietin Inhibitors Therapeutic Market By Types, By Applications, By Distribution Channels and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Angiopoietin Inhibitors Therapeutic Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Angiopoietin Inhibitors Therapeutic Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Angiopoietin Inhibitors Therapeutic Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Angiopoietin Inhibitors Therapeutic Market, By Types Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Angiopoietin-1 inhibitors (AMG780, AB3120)
        2. Angiopoietin-2 inhibitors (Trebananib, MEDI3617, REGN910 CVX-060)

  • 8.   Global Angiopoietin Inhibitors Therapeutic Market, By Applications Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Solid Tumours and Cancers
        2. Vascular diseases (Diabetic Retinopathy, Diabetic Nephropathy)
        3. Asthma

  • 9.   Global Angiopoietin Inhibitors Therapeutic Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Clinics
        3. Others

  • 10.   North America Angiopoietin Inhibitors Therapeutic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Angiopoietin Inhibitors Therapeutic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Angiopoietin Inhibitors Therapeutic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Angiopoietin Inhibitors Therapeutic Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GlaxoSmithKline
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck KGaA
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Agenus
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Amgen
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Regeneron Pharmaceuticals
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients